soul trial oral semaglutide cardiovascular outcomes results 2025 nejm New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj and (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis New data from the SOUL

That framework covers ninety-five percent of every color question you will ever have about the medication in your vial

If we want the next world-changing drug to come from a small biotech, and if we want the UK-US deal to foster genuine, inclusive partnerships, we must ensure that our IP frameworks dont become an overwhelming force multiplier for established power

On that syringe, 100 units equals 1 milliliter

With increasing evidence confirming the valid efficacy of GLP-1RAs in various applications, clinicians must be attentive to hypoglycemia in different agents

In mouse models, dual agonism had superior efficacy for weight loss and glucose control compared to a GLP-1RA alone 9 , with additive effects of the GIPR proposed to act through signaling in beta cells 10 , alpha cells 11 , the CNS (central nervous system) 12,13 and adipocytes 14